IL-15R Inhibitors & Biosimilars
1 drugsAbout IL-15R
Interleukin-15 receptor (IL-15R) is a heterotrimeric protein complex crucial for immune system function. Binding of IL-15 cytokine triggers intracellular signals influencing the development, activation, and survival of immune cells like NK cells and T cells.
Currently, there is no genetic evidence directly linking IL-15R to specific diseases. However, its role in immune regulation makes it a potential target for therapeutic intervention.
IL-15R is targeted by one FDA-approved drug, ANKTIVA, a biologic in the 'other' category. This drug, developed by ALTOR BIOSCIENCE, LLC, was first approved in 2024.
Top IL-15R Drugs
ALTOR BIOSCIENCE, LLC is the only company with an approved drug targeting IL-15R.
The single-player market indicates high barriers to entry or limited interest, requiring careful evaluation of market potential.
IL-15R Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets IL-15R, using enzyme modality.
The lack of small molecule or antibody drugs represents a whitespace opportunity for novel therapeutic modalities.
IL-15R Clinical Trials 5 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on IL-15R. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 1 | 0 | 0 | 1 | - |
| Phase 2 | 3 | 0 | 0 | 3 | - |
| Phase 3 | 1 | 0 | 1 | 0 | 0% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
IL-15R Drug Approval Timeline (2024 - 2024)
The first and most recent drug approval for IL-15R was ANKTIVA in 2024.
The recent approval suggests renewed interest in IL-15R, but further approvals are needed to confirm a sustained upward trend.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 4 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on IL-15R. A trial counts if an approved drug acting on IL-15R is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.